TY - JOUR
T1 - Small bowel injury induced by selective cyclooxygenase-2 inhibitors
T2 - A prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam
AU - Maehata, Yuji
AU - Esaki, Motohiro
AU - Morishita, Toshibumi
AU - Kochi, Shuji
AU - Endo, Shingo
AU - Shikata, Kentaro
AU - Kobayashi, Hiroyuki
AU - Matsumoto, Takayuki
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/4
Y1 - 2012/4
N2 - Background: Selective cyclooxygenase (COX)-2 inhibitors are less harmful to the small bowel mucosa than nonselective anti-inflammatory drugs. We aimed to compare the severity of small bowel mucosal injury in healthy volunteers induced by two selective COX-2 inhibitors, celecoxib and meloxicam, in a randomized, double-blind trial, using capsule endoscopy (CE). Methods: Twenty-nine healthy subjects were randomized to take either celecoxib (200 mg twice daily) or meloxicam (10 mg once daily) for 2 weeks. The incidence and the number of small bowel mucosal injuries (bleeding, ulcers, and erosions) observed by CE were compared between the two groups. Results: The overall incidence of small bowel mucosal injury was not different between the celecoxib group (6 of 14 subjects, 42.9%) and the meloxicam group (4 of 15 subjects, 26.7%, P = 0.45). In subjects with positive CE findings, the number of ulcers was greater in the meloxicam group than in the celecoxib group (P = 0.02), while such a trend was not found with regard to erosions (P = 0.52). The distribution of mucosal lesions within the small bowel was similar in the two groups. Conclusions: Selective COX-2 inhibitors are not completely safe for the small bowel. The mucosal lesions may be less severe with celecoxib than with meloxicam.
AB - Background: Selective cyclooxygenase (COX)-2 inhibitors are less harmful to the small bowel mucosa than nonselective anti-inflammatory drugs. We aimed to compare the severity of small bowel mucosal injury in healthy volunteers induced by two selective COX-2 inhibitors, celecoxib and meloxicam, in a randomized, double-blind trial, using capsule endoscopy (CE). Methods: Twenty-nine healthy subjects were randomized to take either celecoxib (200 mg twice daily) or meloxicam (10 mg once daily) for 2 weeks. The incidence and the number of small bowel mucosal injuries (bleeding, ulcers, and erosions) observed by CE were compared between the two groups. Results: The overall incidence of small bowel mucosal injury was not different between the celecoxib group (6 of 14 subjects, 42.9%) and the meloxicam group (4 of 15 subjects, 26.7%, P = 0.45). In subjects with positive CE findings, the number of ulcers was greater in the meloxicam group than in the celecoxib group (P = 0.02), while such a trend was not found with regard to erosions (P = 0.52). The distribution of mucosal lesions within the small bowel was similar in the two groups. Conclusions: Selective COX-2 inhibitors are not completely safe for the small bowel. The mucosal lesions may be less severe with celecoxib than with meloxicam.
UR - http://www.scopus.com/inward/record.url?scp=84863088511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863088511&partnerID=8YFLogxK
U2 - 10.1007/s00535-011-0501-z
DO - 10.1007/s00535-011-0501-z
M3 - Article
C2 - 22170412
AN - SCOPUS:84863088511
VL - 47
SP - 387
EP - 393
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
SN - 0944-1174
IS - 4
ER -